Engineered immune cells aim to tame childhood autoimmune diseases

NCT ID NCT07283315

Recruiting now Disease control Sponsor: The Children's Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment for children with B cell-related autoimmune diseases like lupus and kidney disease. The therapy uses specially engineered natural killer (NK) cells that target and destroy faulty immune cells. Only 12 children will take part, and the main goal is to see if it is safe and whether it can control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-CD19/BCMA CAR NK cells (KN5601-K)
What this could lead to: If it works, this could offer a new way to control severe autoimmune diseases in children by resetting the immune system without lifelong medication.
What could go wrong: This is a very early, small trial with only 12 participants. The therapy may cause serious side effects or fail to control the disease. Long-term safety and effectiveness are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease Caronte IgA glomerulonephritis steroid-resistant nephrotic syndrome systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES CAR PAEDIATRIC B CELL-RELATED AUTOIMMUNE DISEASES

Contacts and locations

Locations

Children's Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.